Electromed, Inc. (ELMD) - 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended December 31, 2025, and the six months ended on that date. Electromed, Inc. develops, manufactures, and markets High Frequency Chest Wall Oscillation (HFCWO) airway clearance products, primarily the SmartVest System, for homecare and hospital markets. The company operates as a single reporting segment and is classified as a smaller reporting company.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2025 | Six Months Ended Dec 31, 2025 |
|---|---|---|
| Net Revenues | $18.90 million | $35.78 million |
| Gross Profit | $14.82 million (78.4% margin) | $28.02 million (78.3% margin) |
| Operating Income | $3.62 million (19.2% margin) | $6.29 million |
| Net Income | $2.76 million | $4.90 million |
| Diluted EPS | $0.32 | $0.56 |
| Cash and Equivalents | $13.79 million (as of Dec 31, 2025) | |
| Working Capital | ~$36.19 million | |
| Debt | $0 outstanding on $10.0 million revolving credit facility |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 16.3% year-over-year (YoY) for the quarter and 15.7% for the six-month period. Homecare revenue drove this growth, rising 18.4% (quarter) and 15.7% (six months) due to an expanded sales force and higher revenue per representative.
- Profitability: Net income surged 40.3% for the quarter and 42.3% for the six months compared to the prior year, driven by revenue growth and improved gross margins.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 10.0% (quarter) and 9.8% (six months), primarily due to higher payroll and incentive compensation for the expanded sales team. R&D expenses increased significantly (53.0% for the quarter) due to headcount and consulting costs for product enhancements.
- Cash Flow: Net cash provided by operating activities was $3.20 million for the six months ended Dec 31, 2025, a decrease from $5.46 million in the prior year period, largely due to increases in accounts receivable and prepaid expenses.
Outlook, Risks, and Unusual Items
- Capital Resources: The company entered a new $10.0 million revolving credit facility with BMO Bank N.A. in December 2025, maturing in December 2026. There is no outstanding balance. Management believes current working capital and available credit are sufficient for the next 12 months.
- Share Repurchases: Under a $10.0 million authorization approved in September 2025, the company repurchased 146,441 shares for $3.77 million (average $25.72/share) as of December 31, 2025. Approximately $6.24 million remains available under the plan.
- Tax Legislation: The "One Big Beautiful Bill Act" (OBBBA) enacted in July 2025 impacts the deductibility of R&D expenditures. The company plans to accelerate deductions, expecting a cash tax reduction of approximately $428,000 in 2026.
- Risks: Key risks include reimbursement changes from Medicare/Medicaid/private payers, raw material shortages, regulatory compliance, and the ability to renew the credit facility. The company is not currently under any income tax examinations.
Investor Verification Checklist
- Verify the sustainability of the 18.4% homecare revenue growth rate and the associated increase in sales force costs.
- Monitor the impact of the new OBBBA tax legislation on future effective tax rates and cash flows.
- Review the aging of accounts receivable, which increased by $1.6 million in the six-month period, impacting operating cash flow.
- Assess the utilization of the new $10 million credit facility and compliance with covenants (max 2.50x debt ratio, min 1.20x fixed charge coverage).
- Track the remaining $6.24 million in share repurchase authorization and its impact on earnings per share.